News Release

Diagnosis of ovarian cancer delayed by woeful lack of awareness

Most comprehensive survey of women with ovarian cancer ever undertaken suggests raising awareness of the disease could improve outcomes for women

Peer-Reviewed Publication

World Ovarian Cancer Coalition

A global study of women with ovarian cancer has found that two thirds of women had never heard of the disease, or did not know anything about it before their diagnosis. Although nine out of ten had experienced symptoms prior to diagnosis, fewer than half of those women visited a doctor within a month of noticing symptoms.

The World Ovarian Cancer Coalition Every Woman Study is the largest ever review of the experiences of women with ovarian cancer and includes contributions from the clinical community. It presents a bleak picture of the challenges faced by women with ovarian cancer, and those who care for them.

Around the world approximately 239,0001 women are diagnosed with ovarian cancer each year and less than half will survive to five years2. Studies3 have shown that around 15% of women die within 2 months of their diagnosis, with age, emergency presentation and co-morbidities placing them at increased risk. Incidence is rising and is expected to reach 371,000 women a year by 2035 - a 55% increase4.

The survey of over 1,500 women in 44 countries, reveals:

  • Low levels of awareness of ovarian cancer as a global problem resulting in delays in women seeking medical attention
  • Lack of awareness among doctors may also be a significant factor when it comes to delays in diagnosis
  • Variations in access to genetic testing pre and post diagnosis where there is a family history of ovarian cancer
  • Variations in access to specialist treatment - despite this being a vital step that can improve outcomes
  • Variations between countries in terms of what is done well and what is most challenging

Nine in ten of the women in the Every Woman Study experienced symptoms prior to diagnosis and of these, eight in ten consulted a doctor - though less than half within a month and one in ten waited six months.

Across the world, diagnosis took an estimated average of 31 weeks from a woman experiencing symptoms to her diagnosis; for one in ten women diagnosis came more than a year after visiting a doctor.

There are examples of best practice in prevention, diagnosis and treatment of ovarian cancer across the world, but no one country does well in all three areas. This means there are opportunities right now to transform survival in ovarian cancer, simply by learning from what others do well.

Germany, for example has the fastest diagnosis, yet it is estimated that half of women are unlikely to receive specialist care. The UK, by comparison, has the lowest proportion of women diagnosed within a month of visiting a doctor, yet almost universal access to specialist clinicians. Similarly, Australian women had a longer time to diagnosis - but high rates of surgery.

In Canada awareness is high and women seek medical support yet diagnosis is slow. By contrast in Japan, although awareness is very low and fewer women consult their doctors than elsewhere, women who do visit their doctor about symptoms are diagnosed faster than in other countries surveyed.

Elisabeth Baugh, Chair of the Coalition, and CEO of Ovarian Cancer Canada says: "We wanted to find out more about the experiences of women with ovarian cancer and identify what needs to be done right now to tackle this marginalised cancer. The results show that this is a global challenge that can only be taken on by the whole community."

Annwen Jones, CEO of Target Ovarian Cancer in the UK and Co-Chair of The Every Woman Study says: "This study, for the first time, provides powerful evidence of the challenges faced by women diagnosed with ovarian cancer across the world, and sets an agenda for global change. We were especially shocked by the widespread, woeful lack of awareness of ovarian cancer. It is vital that urgent steps are taken in every country to raise awareness of the disease and speed up diagnosis so that we can transform the outlook for the increasing numbers of women and their families affected by ovarian cancer around the world."

Dr Neerja Bhatla, Chair of the FIGO Gynecologic Oncology Committee, Professor at the All India Institute of Medical Sciences, and clinical Co-Chair of the Study says: "We are pleased to have completed this study, which gives us an idea of the changes that can be made to help women with ovarian cancer. We need to build support and funds for action to achieve profound and long-lasting change for women with ovarian cancer."

A survey participant in Australia said "Governments need to do more regarding GPs [family doctors] and their lack of diagnosis and interest in women with ovarian cancer. After diagnosis I googled and all my symptoms were mentioned. GPs were not interested enough and made me feel like a hypochondriac. This went on for months!"

The Every Woman Study is an initiative of the World Ovarian Cancer Coalition that aims to transform survival and wellbeing of women diagnosed with ovarian cancer wherever she lives in the world. The study was undertaken to establish a body of evidence that speaks to the global state of affairs of ovarian cancer. This new and unique evidence base will inform the World Ovarian Cancer Coalition's future work and support advocates all around the world to secure the changes in their countries that women so urgently need and deserve.


The full Every Woman Study will be launched on 18 October, ahead of the European Society for Medical Oncology (ESMO) 2018 Congress, Munich.

Notes to editors:

The World Ovarian Cancer Coalition works with 135 individual partner patient advocacy organizations from 37 countries around the world. Since 2013, the World Ovarian Day Campaign has reached well over 1,000,000 - with people taking part frequently from at least 50 countries and in 45 different languages.

Following a survey of members about their priorities for action, a series of interviews among women and clinicians in 16 countries was conducted, as well as desk research. The findings formed the basis of the Every Woman Study Online Survey, completed by 1531 women in 44 countries between March and May 2018.

All reports will be available here after the embargo lifts

Every Woman Study - Expert Advisory Panel

Dr Neerja Bhatla - Co-Chair, India
Annwen Jones - Co-Chair and World Ovarian Cancer Coalition Board member, UK
Dr Tracey Adams - South Africa
Amanda Benites - Patient Representative, Brazil
Dr Stephanie Blank - USA
Robin Cohen - Nurse representative and World Ovarian Cancer Coalition Board Member, USA
Diane Gardiner - Patient Representative, Australia
Sylvia Gregory - Patient Representative, Italy
Professor Amit Oza - Clinical Lead, Canada
Makiko Suzuki - Patient Representative, Japan

About ovarian cancer

Ovarian cancer is diagnosed annually in nearly a quarter of a million women globally, and is responsible for 140,000 deaths each year. Statistics show that just 45% of women with ovarian cancer are likely to survive for five years compared to up to 89% of women with breast cancer.

Symptoms are often misdiagnosed, as they can be confused with symptoms of other less severe illnesses, particularly gastrointestinal complaints. The majority of patients are only identified in the advanced stages when the disease becomes more difficult to treat. There is no routine, simple test to accurately detect ovarian cancer.


  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86.
  2. Allemani, ClaudiaBouzbid, S et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries of 71 countries, The Lancet, volume 391, issue 10125-107

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.